Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
07 2021
Historique:
received: 09 03 2021
revised: 04 05 2021
accepted: 08 05 2021
pubmed: 24 5 2021
medline: 1 2 2022
entrez: 23 5 2021
Statut: ppublish

Résumé

To investigate the recovery trajectory and predictors of outcome for swallowing difficulties following head and neck cancer treatment in a large prospective cohort. Data from 5404 participants of the Head and Neck 5000 study were collected from 2011 to 2014. Patient-reported swallowing was measured using the EORTC HN35, recorded at baseline (pre-treatment) and 4 and 12 months post-baseline. Mixed-effects linear multivariable regression was used to investigate time trends, compare cancer sites, and identify associations between clinical, socio-demographic and lifestyle variables. 2458 participants with non-recurrent oral (29%) oropharyngeal (46%) and laryngeal (25%) cancer were included in the analysis. There was a clinically significant deterioration in scores between baseline and four months for swallowing (11.7 points; 95% CI 10.7-12.8) and trouble with social eating (17.9 points; 95% CI 16.7-19.2), but minimal difference between baseline and 12 months. Predictors of better swallowing and social eating were participants with larynx cancer, early-stage disease, treatment type, age, gender, co-morbidity, socio-economic status, smoking behaviour and cohabitation. Swallowing problems persist up to a year after head and neck cancer treatment. These findings identify disease and demographic characteristics for particularly vulnerable groups, supporting the need for holistic interventions to help improve swallowing outcomes. People diagnosed with head and neck cancer at risk of severe eating and drinking problems following treatment can be identified earlier in the pathway, receive more accurate information about early and late post-treatment side-effects, which can inform shared decision-making discussions.

Identifiants

pubmed: 34023744
pii: S1368-8375(21)00167-6
doi: 10.1016/j.oraloncology.2021.105344
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105344

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Joanne M Patterson (JM)

Liverpool Head and Neck Centre, School of Health Science, University of Liverpool, United Kingdom. Electronic address: joanne.patterson@liverpool.ac.uk.

Liya Lu (L)

Population Health Sciences Institute, Newcastle University Centre for Cancer, Newcastle University, United Kingdom. Electronic address: Liya.Lu@newcastle.ac.uk.

Laura-Jayne Watson (LJ)

South Tyneside and Sunderland NHS Foundation Trust, United Kingdom. Electronic address: Laura-Jayne.Watson@chsft.nhs.uk.

Sam Harding (S)

Bristol Speech and Language Therapy Research Unit, Southmead Hospital North Bristol NHS Hospital Trust, Bristol BS10 5NB, United Kingdom. Electronic address: Samantha.Harding@nbt.nhs.uk.

Andy R Ness (AR)

NIHR Bristol Biomedical Research Centre, University Hospitals Bristol, Bristol BS2 8AE, United Kingdom. Electronic address: Andy.Ness@bristol.ac.uk.

Steve Thomas (S)

NIHR Bristol Biomedical Research Centre, University Hospitals Bristol, Bristol BS2 8AE, United Kingdom. Electronic address: Steve.Thomas@bristol.ac.uk.

Andrea Waylen (A)

NIHR Bristol Biomedical Research Centre, University Hospitals Bristol, Bristol BS2 8AE, United Kingdom. Electronic address: Andrea.Waylen@bristol.ac.uk.

Tim Waterboer (T)

Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Germany. Electronic address: f.T.Waterboer@dkfz-heidelberg.de.

Linda Sharp (L)

Population Health Sciences Institute, Newcastle University Centre for Cancer, Newcastle University, United Kingdom. Electronic address: Linda.Sharp@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH